New stock news | Thai Li Biotechnology submitted an application to the Hong Kong Stock Exchange.

According to the disclosure of the Hong Kong Stock Exchange on January 29th, Thai Rebio Limited (referred to as Thai Rebio) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC as its exclusive sponsor. The prospectus reveals that Thai Rebio is a clinical-stage biopharmaceutical company founded in 2017, focusing on the discovery and development of innovative cancer therapies. The company's drug portfolio includes four candidate drugs, including a core product TSN1611 in Phase 2 clinical trials, an additional clinical-stage candidate TSN222, and two preclinical candidate drugs TSNA1789 and TSNA3339. The company's core candidate drug TSN1611 is a highly selective oral KRAS G12D inhibitor. KRAS G12D, as one of the most common oncogenic driver mutations, has historically been a treatment challenge. TSN1611 is currently undergoing Phase 2 clinical trials in the United States and China, with plans to advance a key registration clinical trial for the treatment of non-small cell lung cancer (NSCLC) in China.